>>Signaling Pathways>> Apoptosis>> APC>>Apcin

Apcin

Catalog No.GC18518

Cdc20의 리간드인 Apcin은 강력하고 경쟁력 있는 anaphase-promoting complex/cyclosome(APC/C(Cdc20)) E3 ligase 활성 억제제입니다. Apcin은 Cdc20에 결합하고 기질 인식을 방지하여 APC/C 의존적 유비퀴틸화를 경쟁적으로 억제합니다. Apcin은 WD40-domain 측면의 D-box-binding pocket을 차지하고 유사분열을 연장할 수 있습니다.

Products are for research use only. Not for human use. We do not sell to patients.

Apcin Chemical Structure

Cas No.: 300815-04-7

Size 가격 재고 수량
1mg
US$26.00
재고 있음
5mg
US$90.00
재고 있음
10mg
US$144.00
재고 있음
25mg
US$288.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Apcin is an inhibitor of the E3 ligase activity of the mitotic anaphase-promoting complex/cyclosome (APC/C). Apcin competitively binds to Cdc20 and prevents substrate interaction and ubiquitylation required for continuation of mitosis. Apcin enhances the effect of the APC/C inhibitor N-4-tosyl-L-arginine methyl ester and its prodrug, proTAME, leading to an increase in the number of cells in mitosis, a longer mitotic duration, and greater stabilization of cyclin B1, cycB1-NT, securin, and cyclin A2. Apcin, in combination with proTAME, synergistically increases apoptosis in multiple myeloma cells.

References:
[1]. Sackton, K.L., Dimova, N., Zeng, X., et al. Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C Nature 514(7524), 646-649 (2014).
[2]. Lub, S., Maes, A., De Veirman, K., et al. Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells Oncotarget 7(4), 4062-4076 (2016).

리뷰

Review for Apcin

Average Rating: 5 ★★★★★ (Based on Reviews and 14 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Apcin

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.